Visfatin mediates doxorubicin resistance in human non-small-cell lung cancerviaAkt-mediated up-regulation of ABCC1

Author:

Cao Zhili1,Liang Naixin1ORCID,Yang Huaxia2,Li Shanqing1

Affiliation:

1. Department of Thoracic Surgery; Peking Union Medical College Hospital; Peking Union Medical College and Chinese Academy of Medical Sciences; Beijing 100730 China

2. Department of Rheumatology; Peking Union Medical College Hospital; Peking Union Medical College and Chinese Academy of Medical Sciences; Beijing 100730 China

Funder

Specialized Research Fund for the Doctoral Program of Higher Education

Capital Special Project for Featured Clinical Application

Peking Union Medical College Hospital Youth Researcher

Peking Union Medical College Youth Teacher

Beijing Municipal Science and Technology Project

Publisher

Wiley

Subject

Cell Biology,General Medicine

Reference24 articles.

1. Cancer statistics, 2015;Siegel;CA Cancer J Clin,2015

2. Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group;Gaspar;J Clin Oncol Off J Am Soc Clin Oncol,2005

3. Role of RLIP76 in doxorubicin resistance in lung cancer;Vatsyayan;Int J Oncol,2009

4. Doxorubicin-induced apoptosis: implications in cardiotoxicity;Kalyanaraman;Mol Cell Biochem,2002

5. Activation of the ubiquitin-proteasome system in doxorubicin cardiomyopathy;Ranek;Curr Hypertens Rep,2009

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3